Progress of drug resistance mechanism of ibrutinib
10.3760/cma.j.issn.1009﹣9921.2019.07.013
- VernacularTitle:依鲁替尼耐药机制的研究进展
- Author:
Jingjing YUAN
1
;
Keshu ZHOU
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院血液科 450008
- Keywords:
Lymphoma,non﹣Hodgkin;
Leukemia,lymphocytic,chronic;
Ibrutinib
- From:
Journal of Leukemia & Lymphoma
2019;28(7):434-437
- CountryChina
- Language:Chinese
-
Abstract:
As a novel molecular targeted anti﹣tumor drug, it has been proved that ibrutinib has remarkable anti﹣tumor activity and is characterized by high efficiency and low toxicity. However, the risks of drug resistance, safety, and disease transformation are gradually concerned. This review focused on the research progress of ibrutinib′s drug resistance mechanism in various B﹣cell non﹣Hodgkin lymphomas.
